TAK1 is a pivotal therapeutic target for tumor progression and bone destruction in myeloma

Along with tumor progression, the bone marrow microenvironment is skewed in multiple myeloma (MM), which underlies the unique pathophysiology of MM and confers aggressiveness and drug resistance in MM cells. TGF-b-activated kinase-1 (TAK1) mediates a wide range of intracellular signaling pathways. W...

Descripción completa

Detalles Bibliográficos
Autores principales: Teramachi, Jumpei, Tenshin, Hirofumi, Hiasa, Masahiro, Oda, Asuka, Bat-Erdene, Ariunzaya, Harada, Takeshi, Nakamura, Shingen, Ashtar, Mohannad, Shimizu, So, Iwasa, Masami, Sogabe, Kimiko, Oura, Masahiro, Fujii, Shiro, Kagawa, Kumiko, Miki, Hirokazu, Endo, Itsuro, Haneji, Tatsuji, Matsumoto, Toshio, Abe, Masahiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8094086/
https://www.ncbi.nlm.nih.gov/pubmed/32273474
http://dx.doi.org/10.3324/haematol.2019.234476

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8094086/
https://www.ncbi.nlm.nih.gov/pubmed/32273474
http://dx.doi.org/10.3324/haematol.2019.234476

Ejemplares similares